Pharmacological inhibition of tolllike receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis

Swati Bhattacharyya*, Wenxia Wang, Zenshiro Tamaki, Bo Shi, Anjana Yeldandi, Yasuhiro Tsukimi, Masashi Yamasaki, John Varga

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) is a poorly understood heterogeneous condition with progressive multi-organ fibrosis. Recent genetic and genomic evidence suggest a pathogenic role for dysregulated innate immunity and toll-like receptor (TLR) activity in SSc. Levels of both TLR4, as well as certain endogenous TLR ligands, are elevated in skin and lung tissues from patients with SSc and correlate with clinical disease parameters. Conversely, genetic targeting of TLR4 or its endogenous "damage-associated" ligands ameliorates progressive tissue fibrosis. Targeting TLR4 signaling therefore represents a pharmacological strategy to prevent intractable fibrosis. We examined the effect of TAK242, a small molecule TLR4 inhibitor, in preclinical fibrosis models and in SSc fibroblasts. TAK242 treatment prevented, promoted regression of, bleomycin-induced dermal and pulmonary fibrosis, and reduced the expression of several pro-fibrotic mediators. Furthermore, TAK242 ameliorated peritoneal fibrosis and reduced spontaneous hypodermal thickness in TSK/+ mice. Importantly, TAK242 abrogated collagen synthesis and myofibroblasts differentiation in explanted constitutively active SSc fibroblast. Altogether, these findings identify TAK242 as an anti-fibrotic agent in preclinical models of organ fibrosis. TAK242 might potentially represent a novel strategy for the treatment of SSc and other fibrotic diseases.

Original languageEnglish (US)
Article number2434
JournalFrontiers in immunology
Volume9
Issue numberOCT
DOIs
StatePublished - Oct 23 2018

Fingerprint

Systemic Scleroderma
Fibrosis
Pharmacology
Toll-Like Receptors
Fibroblasts
Peritoneal Fibrosis
Ligands
Skin
Myofibroblasts
Pulmonary Fibrosis
Bleomycin
Innate Immunity
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
Collagen
Lung
Therapeutics

Keywords

  • Fibrosis
  • IL-6
  • Resatorvid
  • SSc
  • Systemic sclerosis
  • TAK242
  • TLR
  • Toll-like receptor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{66e13e1e33b640eaa59b6d452aa8eba6,
title = "Pharmacological inhibition of tolllike receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis",
abstract = "Systemic sclerosis (SSc) is a poorly understood heterogeneous condition with progressive multi-organ fibrosis. Recent genetic and genomic evidence suggest a pathogenic role for dysregulated innate immunity and toll-like receptor (TLR) activity in SSc. Levels of both TLR4, as well as certain endogenous TLR ligands, are elevated in skin and lung tissues from patients with SSc and correlate with clinical disease parameters. Conversely, genetic targeting of TLR4 or its endogenous {"}damage-associated{"} ligands ameliorates progressive tissue fibrosis. Targeting TLR4 signaling therefore represents a pharmacological strategy to prevent intractable fibrosis. We examined the effect of TAK242, a small molecule TLR4 inhibitor, in preclinical fibrosis models and in SSc fibroblasts. TAK242 treatment prevented, promoted regression of, bleomycin-induced dermal and pulmonary fibrosis, and reduced the expression of several pro-fibrotic mediators. Furthermore, TAK242 ameliorated peritoneal fibrosis and reduced spontaneous hypodermal thickness in TSK/+ mice. Importantly, TAK242 abrogated collagen synthesis and myofibroblasts differentiation in explanted constitutively active SSc fibroblast. Altogether, these findings identify TAK242 as an anti-fibrotic agent in preclinical models of organ fibrosis. TAK242 might potentially represent a novel strategy for the treatment of SSc and other fibrotic diseases.",
keywords = "Fibrosis, IL-6, Resatorvid, SSc, Systemic sclerosis, TAK242, TLR, Toll-like receptor",
author = "Swati Bhattacharyya and Wenxia Wang and Zenshiro Tamaki and Bo Shi and Anjana Yeldandi and Yasuhiro Tsukimi and Masashi Yamasaki and John Varga",
year = "2018",
month = "10",
day = "23",
doi = "10.3389/fimmu.2018.02434",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

Pharmacological inhibition of tolllike receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis. / Bhattacharyya, Swati; Wang, Wenxia; Tamaki, Zenshiro; Shi, Bo; Yeldandi, Anjana; Tsukimi, Yasuhiro; Yamasaki, Masashi; Varga, John.

In: Frontiers in immunology, Vol. 9, No. OCT, 2434, 23.10.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacological inhibition of tolllike receptor-4 signaling by TAK242 prevents and induces regression of experimental organ fibrosis

AU - Bhattacharyya, Swati

AU - Wang, Wenxia

AU - Tamaki, Zenshiro

AU - Shi, Bo

AU - Yeldandi, Anjana

AU - Tsukimi, Yasuhiro

AU - Yamasaki, Masashi

AU - Varga, John

PY - 2018/10/23

Y1 - 2018/10/23

N2 - Systemic sclerosis (SSc) is a poorly understood heterogeneous condition with progressive multi-organ fibrosis. Recent genetic and genomic evidence suggest a pathogenic role for dysregulated innate immunity and toll-like receptor (TLR) activity in SSc. Levels of both TLR4, as well as certain endogenous TLR ligands, are elevated in skin and lung tissues from patients with SSc and correlate with clinical disease parameters. Conversely, genetic targeting of TLR4 or its endogenous "damage-associated" ligands ameliorates progressive tissue fibrosis. Targeting TLR4 signaling therefore represents a pharmacological strategy to prevent intractable fibrosis. We examined the effect of TAK242, a small molecule TLR4 inhibitor, in preclinical fibrosis models and in SSc fibroblasts. TAK242 treatment prevented, promoted regression of, bleomycin-induced dermal and pulmonary fibrosis, and reduced the expression of several pro-fibrotic mediators. Furthermore, TAK242 ameliorated peritoneal fibrosis and reduced spontaneous hypodermal thickness in TSK/+ mice. Importantly, TAK242 abrogated collagen synthesis and myofibroblasts differentiation in explanted constitutively active SSc fibroblast. Altogether, these findings identify TAK242 as an anti-fibrotic agent in preclinical models of organ fibrosis. TAK242 might potentially represent a novel strategy for the treatment of SSc and other fibrotic diseases.

AB - Systemic sclerosis (SSc) is a poorly understood heterogeneous condition with progressive multi-organ fibrosis. Recent genetic and genomic evidence suggest a pathogenic role for dysregulated innate immunity and toll-like receptor (TLR) activity in SSc. Levels of both TLR4, as well as certain endogenous TLR ligands, are elevated in skin and lung tissues from patients with SSc and correlate with clinical disease parameters. Conversely, genetic targeting of TLR4 or its endogenous "damage-associated" ligands ameliorates progressive tissue fibrosis. Targeting TLR4 signaling therefore represents a pharmacological strategy to prevent intractable fibrosis. We examined the effect of TAK242, a small molecule TLR4 inhibitor, in preclinical fibrosis models and in SSc fibroblasts. TAK242 treatment prevented, promoted regression of, bleomycin-induced dermal and pulmonary fibrosis, and reduced the expression of several pro-fibrotic mediators. Furthermore, TAK242 ameliorated peritoneal fibrosis and reduced spontaneous hypodermal thickness in TSK/+ mice. Importantly, TAK242 abrogated collagen synthesis and myofibroblasts differentiation in explanted constitutively active SSc fibroblast. Altogether, these findings identify TAK242 as an anti-fibrotic agent in preclinical models of organ fibrosis. TAK242 might potentially represent a novel strategy for the treatment of SSc and other fibrotic diseases.

KW - Fibrosis

KW - IL-6

KW - Resatorvid

KW - SSc

KW - Systemic sclerosis

KW - TAK242

KW - TLR

KW - Toll-like receptor

UR - http://www.scopus.com/inward/record.url?scp=85055768505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055768505&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.02434

DO - 10.3389/fimmu.2018.02434

M3 - Article

C2 - 30405628

AN - SCOPUS:85055768505

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - OCT

M1 - 2434

ER -